Women at heart: Introducing gender cardio-oncology
Maria Laura Canale(Ospedale Versilia), Furio Colivicchi(Ospedale San Filippo Neri), Damiana Fiscella, Giuseppina Gallucci, Stefania Angela Di Fusco(ASL Roma), Massimiliano Camilli(Università Cattolica del Sacro Cuore), Daniela Pavan(Azienda Unità Sanitaria Locale di Ferrara), Michele Massimo Gulizia(Ospedale Garibaldi), Andrea Camerini(Ospedale Versilia), Domenico Gabrielli(Azienda Ospedaliera San Camillo-Forlanini), Andrea Paccone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Nicola Maurea(Cancer Institute (WIA)), Fabio Maria Turazza, Fabrizio Oliva(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Giulia Russo(University of Catania), Irma Bisceglia(Azienda Ospedaliera San Camillo-Forlanini), Chiara Lestuzzi
Cited by 14
Related Papers
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
In silico clinical trials: concepts and early adoptions
|Briefings in Bioinformatics|2018|267
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
|Journal of Clinical Oncology|2017|186
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116
Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use
|Journal of Cardiovascular Pharmacology|2020|111